HMG modifications and nuclear function

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1799, Issue 1-2, 2010, Pages 28-36

  Zhang, Qingchun ^a   Wang, Yinsheng ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

High mobility group protein; Mass spectrometry; Post translational modification

Indexed keywords

DNA; HIGH MOBILITY GROUP A PROTEIN; HIGH MOBILITY GROUP A1A PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP PROTEIN;

ACETYLATION; BIOLOGICAL ACTIVITY; BLEACHING; CELL CYCLE; CHEMICAL MODIFICATION; DNA BINDING; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; CELL NUCLEUS; HIGH MOBILITY GROUP PROTEINS; HMGA PROTEINS; HMGB PROTEINS; HMGN PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN PROCESSING, POST-TRANSLATIONAL;

MAMMALIA;

EID: 74549129403     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2009.11.009     Document Type: Review

References (129)

1. Bustin M., and Reeves R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog. Nucleic Acid Res. Mol. Biol. 54 (1996) 35-100
2. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol. Cell. Biol. 19 (1999) 5237-5246
3. Bianchi M.E., and Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. Curr. Opin. Genet. Dev. 15 (2005) 496-506
4. Abe N., Watanabe T., Masaki T., Mori T., Sugiyama M., Uchimura H., Fujioka Y., Chiappetta G., Fusco A., and Atomi Y. Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res. 60 (2000) 3117-3122
5. Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem. Sci. 26 (2001) 152-153
6. Reeves R., and Nissen M.S. The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J. Biol. Chem. 265 (1990) 8573-8582
7. Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene 277 (2001) 63-81
8. Reeves R., and Beckerbauer L. HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim. Biophys. Acta 1519 (2001) 13-29
9. Liu J., Schiltz J.F., Ashar H.R., and Chada K.K. HMGA1 is required for normal sperm development. Mol. Reprod. Dev. 66 (2003) 81-89
10. Fedele M., Fidanza V., Battista S., Pentimalli F., Klein-Szanto A.J., Visone R., De Martino I., Curcio A., Morisco C., Del Vecchio L., Baldassarre G., Arra C., Viglietto G., Indolfi C., Croce C.M., and Fusco A. Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res. 66 (2006) 2536-2543
11. Caron L., Bost F., Prot M., Hofman P., and Binetruy B. A new role for the oncogenic high-mobility group A2 transcription factor in myogenesis of embryonic stem cells. Oncogene 24 (2005) 6281-6291
12. Fusco A., and Fedele M. Roles of HMGA proteins in cancer. Nat. Rev., Cancer 7 (2007) 899-910
13. Anand A., and Chada K. In vivo modulation of HMGIC reduces obesity. Nat. Genet. 24 (2000) 377-380
14. Foti D., Chiefari E., Fedele M., Iuliano R., Brunetti L., Paonessa F., Manfioletti G., Barbetti F., Brunetti A., Croce C.M., Fusco A., and Brunetti A. Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. Nat. Med. 11 (2005) 765-773
15. Schlueter C., Hauke S., Loeschke S., Wenk H.H., and Bullerdiek J. HMGA1 proteins in human atherosclerotic plaques. Pathol. Res. Pract. 201 (2005) 101-107
16. Giancotti V., Bandiera A., Sindici C., Perissin L., and Crane-Robinson C. Calcium-dependent ADP-ribosylation of high-mobility-group I (HMGI) proteins. Biochem. J. 317 Pt 3 (1996) 865-870
17. Lund T., Holtlund J., and Laland S.G. On the phosphorylation of low molecular mass HMG (high mobility group) proteins in Ehrlich ascites cells. FEBS Lett. 180 (1985) 275-279
18. Lund T., Holtlund J., Fredriksen M., and Laland S.G. On the presence of two new high mobility group-like proteins in HeLa S3 cells. FEBS Lett. 152 (1983) 163-167
19. Cleynen I., and Van de Ven W.J. The HMGA proteins: a myriad of functions. Int. J. Oncol. 32 (2008) 289-305
20. Lund T., and Laland S.G. The metaphase specific phosphorylation of HMG I. Biochem. Biophys. Res. Commun. 171 (1990) 342-347
21. Nissen M.S., Langan T.A., and Reeves R. Phosphorylation by cdc2 kinase modulates DNA binding activity of high mobility group I nonhistone chromatin protein. J. Biol. Chem. 266 (1991) 19945-19952
22. Reeves R., Langan T.A., and Nissen M.S. Phosphorylation of the DNA-binding domain of nonhistone high-mobility group I protein by cdc2 kinase: reduction of binding affinity. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 1671-1675
23. Pierantoni G.M., Fedele M., Pentimalli F., Benvenuto G., Pero R., Viglietto G., Santoro M., Chiariotti L., and Fusco A. High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. Oncogene 20 (2001) 6132-6141
24. Zhang Q., and Wang Y. Homeodomain-interacting protein kinase-2 (HIPK2) phosphorylates HMGA1a at Ser-35, Thr-52, and Thr-77 and modulates its DNA binding affinity. J. Proteome Res. 6 (2007) 4711-4719
25. Harrer M., Luhrs H., Bustin M., Scheer U., and Hock R. Dynamic interaction of HMGA1a proteins with chromatin. J. Cell Sci. 117 (2004) 3459-3471
26. Pierantoni G.M., Rinaldo C., Mottolese M., Di Benedetto A., Esposito F., Soddu S., and Fusco A. High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J. Clin. Invest. 117 (2007) 693-702
27. Pierantoni G.M., Rinaldo C., Esposito F., Mottolese M., Soddu S., and Fusco A. High mobility group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell Death Differ. 13 (2006) 1554-1563
28. Palvimo J., and Linnala-Kankkunen A. Identification of sites on chromosomal protein HMG-I phosphorylated by casein kinase II. FEBS Lett. 257 (1989) 101-104
29. Jiang X., and Wang Y. Acetylation and phosphorylation of high-mobility group A1 proteins in PC-3 human tumor cells. Biochemistry 45 (2006) 7194-7201
30. Ferranti P., Malorni A., Marino G., Pucci P., Goodwin G.H., Manfioletti G., and Giancotti V. Mass spectrometric analysis of the HMGY protein from Lewis lung carcinoma. Identification of phosphorylation sites. J. Biol. Chem. 267 (1992) 22486-22489
31. Wang D.Z., Ray P., and Boothby M. Interleukin 4-inducible phosphorylation of HMG-I(Y) is inhibited by rapamycin. J. Biol. Chem. 270 (1995) 22924-22932
32. Xiao D.M., Pak J.H., Wang X., Sato T., Huang F.L., Chen H.C., and Huang K.P. Phosphorylation of HMG-I by protein kinase C attenuates its binding affinity to the promoter regions of protein kinase C gamma and neurogranin/RC3 genes. J. Neurochem. 74 (2000) 392-399
33. Banks G.C., Li Y., and Reeves R. Differential in vivo modifications of the HMGI(Y) nonhistone chromatin proteins modulate nucleosome and DNA interactions. Biochemistry 39 (2000) 8333-8346
34. Pentimalli F., Palmieri D., Pacelli R., Garbi C., Cesari R., Martin E., Pierantoni G.M., Chieffi P., Croce C.M., Costanzo V., Fedele M., and Fusco A. HMGA1 protein is a novel target of the ATM kinase. Eur. J. Cancer 44 (2008) 2668-2679
35. O'Neill T., Dwyer A.J., Ziv Y., Chan D.W., Lees-Miller S.P., Abraham R.H., Lai J.H., Hill D., Shiloh Y., Cantley L.C., and Rathbun G.A. Utilization of oriented peptide libraries to identify substrate motifs selected by ATM. J. Biol. Chem. 275 (2000) 22719-22727
36. Diana F., Sgarra R., Manfioletti G., Rustighi A., Poletto D., Sciortino M.T., Mastino A., and Giancotti V. A link between apoptosis and degree of phosphorylation of high mobility group A1a protein in leukemic cells. J. Biol. Chem. 276 (2001) 11354-11361
37. Edberg D.D., Adkins J.N., Springer D.L., and Reeves R. Dynamic and differential in vivo modifications of the isoform HMGA1a and HMGA1b chromatin proteins. J. Biol. Chem. 280 (2005) 8961-8973
38. Zhang Q., Zhang K., Zou Y., Perna A., and Wang Y. A quantitative study on the in-vitro and in-vivo acetylation of high mobility group A1 proteins. J. Am. Soc. Mass Spectrom. 18 (2007) 1569-1578
39. Munshi N., Agalioti T., Lomvardas S., Merika M., Chen G., and Thanos D. Coordination of a transcriptional switch by HMGI(Y) acetylation. Science 293 (2001) 1133-1136
40. Munshi N., Merika M., Yie J., Senger K., Chen G., and Thanos D. Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome. Mol. Cell 2 (1998) 457-467
41. Edberg D.D., Bruce J.E., Siems W.F., and Reeves R. In vivo posttranslational modifications of the high mobility group A1a proteins in breast cancer cells of differing metastatic potential. Biochemistry 43 (2004) 11500-11515
42. Sgarra R., Diana F., Rustighi A., Manfioletti G., and Giancotti V. Increase of HMGA1a protein methylation is a distinctive characteristic of leukaemic cells induced to undergo apoptosis. Cell Death Differ. 10 (2003) 386-389
43. Sgarra R., Diana F., Bellarosa C., Dekleva V., Rustighi A., Toller M., Manfioletti G., and Giancotti V. During apoptosis of tumor cells HMGA1a protein undergoes methylation: identification of the modification site by mass spectrometry. Biochemistry 42 (2003) 3575-3585
44. Zou Y., and Wang Y. Tandem mass spectrometry for the examination of the posttranslational modifications of high-mobility group A1 proteins: symmetric and asymmetric dimethylation of Arg25 in HMGA1a protein. Biochemistry 44 (2005) 6293-6301
45. McBride A.E., and Silver P.A. State of the arg: protein methylation at arginine comes of age. Cell 106 (2001) 5-8
46. Miranda T.B., Webb K.J., Edberg D.D., Reeves R., and Clarke S. Protein arginine methyltransferase 6 specifically methylates the nonhistone chromatin protein HMGA1a. Biochem. Biophys. Res. Commun. 336 (2005) 831-835
47. Sgarra R., Lee J., Tessari M.A., Altamura S., Spolaore B., Giancotti V., Bedford M.T., and Manfioletti G. The AT-hook of the chromatin architectural transcription factor high mobility group A1a is arginine-methylated by protein arginine methyltransferase 6. J. Biol. Chem. 281 (2006) 3764-3772
48. Zou Y., and Wang Y. Mass spectrometric analysis of high-mobility group proteins and their post-translational modifications in normal and cancerous human breast tissues. J. Proteome Res. 6 (2007) 2304-2314
49. Zou Y., Webb K., Perna A.D., Zhang Q., Clarke S., and Wang Y. A mass spectrometric study on the in vitro methylation of HMGA1a and HMGA1b proteins by PRMTs: methylation specificity, the effect of binding to AT-rich duplex DNA, and the effect of C-terminal phosphorylation. Biochemistry 46 (2007) 7896-7906
50. Manfioletti G., Giancotti V., Bandiera A., Buratti E., Sautiere P., Cary P., Crane-Robinson C., Coles B., and Goodwin G.H. cDNA cloning of the HMGI-C phosphoprotein, a nuclear protein associated with neoplastic and undifferentiated phenotypes. Nucleic Acids Res. 19 (1991) 6793-6797
51. Monzen K., Ito Y., Naito A.T., Kasai H., Hiroi Y., Hayashi D., Shiojima I., Yamazaki T., Miyazono K., Asashima M., Nagai R., and Komuro I. A crucial role of a high mobility group protein HMGA2 in cardiogenesis. Nat. Cell Biol. 10 (2008) 567-574
52. Zhou X., Benson K.F., Ashar H.R., and Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376 (1995) 771-774
53. Weedon M.N., Lettre G., Freathy R.M., Lindgren C.M., Voight B.F., Perry J.R., Elliott K.S., Hackett R., Guiducci C., Shields B., Zeggini E., Lango H., Lyssenko V., Timpson N.J., Burtt N.P., Rayner N.W., Saxena R., Ardlie K., Tobias J.H., Ness A.R., Ring S.M., Palmer C.N., Morris A.D., Peltonen L., Salomaa V., Davey Smith G., Groop L.C., Hattersley A.T., McCarthy M.I., Hirschhorn J.N., and Frayling T.M. A common variant of HMGA2 is associated with adult and childhood height in the general population. Nat. Genet. 39 (2007) 1245-1250
54. Zaidi M.R., Okada Y., and Chada K.K. Misexpression of full-length HMGA2 induces benign mesenchymal tumors in mice. Cancer Res. 66 (2006) 7453-7459
55. Fedele M., Battista S., Kenyon L., Baldassarre G., Fidanza V., Klein-Szanto A.J., Parlow A.F., Visone R., Pierantoni G.M., Outwater E., Santoro M., Croce C.M., and Fusco A. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 21 (2002) 3190-3198
56. Fedele M., Visone R., De Martino I., Troncone G., Palmieri D., Battista S., Ciarmiello A., Pallante P., Arra C., Melillo R.M., Helin K., Croce C.M., and Fusco A. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 9 (2006) 459-471
57. Schwanbeck R., Manfioletti G., and Wisniewski J.R. Architecture of high mobility group protein I-C.DNA complex and its perturbation upon phosphorylation by Cdc2 kinase. J. Biol. Chem. 275 (2000) 1793-1801
58. Goodwin G. The high mobility group protein, HMGI-C, Int. J. Biochem. Cell Biol. 30 (1998) 761-766
59. Di Agostino S., Fedele M., Chieffi P., Fusco A., Rossi P., Geremia R., and Sette C. Phosphorylation of high-mobility group protein A2 by Nek2 kinase during the first meiotic division in mouse spermatocytes. Mol. Biol. Cell 15 (2004) 1224-1232
60. Sgarra R., Maurizio E., Zammitti S., Lo Sardo A., Giancotti V., and Manfioletti G. Macroscopic differences in HMGA oncoproteins post-translational modifications: C-terminal phosphorylation of HMGA2 affects its DNA binding properties. J. Proteome Res. 8 (2009) 2978-2989
61. Cao X., Clavijo C., Li X., Lin H.H., Chen Y., Shih H.M., and Ann D.K. SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome. Mol. Cancer Ther. 7 (2008) 923-934
62. Thomas J.O., and Travers A.A. HMG1 and 2, and related 'architectural' DNA-binding proteins. Trends Biochem. Sci. 26 (2001) 167-174
63. Agresti A., and Bianchi M.E. HMGB proteins and gene expression. Curr. Opin. Genet. Dev. 13 (2003) 170-178
64. Calogero S., Grassi F., Aguzzi A., Voigtlander T., Ferrier P., Ferrari S., and Bianchi M.E. The lack of chromosomal protein HMG1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet. 22 (1999) 276-280
65. Bonaldi T., Langst G., Strohner R., Becker P.B., and Bianchi M.E. The DNA chaperone HMGB1 facilitates ACF/CHRAC-dependent nucleosome sliding. EMBO J. 21 (2002) 6865-6873
66. Travers A.A. Priming the nucleosome: a role for HMGB proteins?. EMBO Rep. 4 (2003) 131-136
67. Najima Y., Yahagi N., Takeuchi Y., Matsuzaka T., Sekiya M., Nakagawa Y., Amemiya-Kudo M., Okazaki H., Okazaki S., Tamura Y., Iizuka Y., Ohashi K., Harada K., Gotoda T., Nagai R., Kadowaki T., Ishibashi S., Yamada N., Osuga J., and Shimano H. High mobility group protein-B1 interacts with sterol regulatory element-binding proteins to enhance their DNA binding. J. Biol. Chem. 280 (2005) 27523-27532
68. Scaffidi P., Misteli T., and Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418 (2002) 191-195
69. Muller S., Scaffidi P., Degryse B., Bonaldi T., Ronfani L., Agresti A., Beltrame M., and Bianchi M.E. New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J. 20 (2001) 4337-4340
70. Campana L., Bosurgi L., and Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr. Opin. Immunol. 20 (2008) 518-523
71. Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., Tanji N., Lu Y., Lalla E., Fu C., Hofmann M.A., Kislinger T., Ingram M., Lu A., Tanaka H., Hori O., Ogawa S., Stern D.M., and Schmidt A.M. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405 (2000) 354-360
72. Apetoh L., Tesniere A., Ghiringhelli F., Kroemer G., and Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 68 (2008) 4026-4030
73. Sterner R., Vidali G., and Allfrey V.G. Studies of acetylation and deacetylation in high mobility group proteins. Identification of the sites of acetylation in HMG-1. J. Biol. Chem. 254 (1979) 11577-11583
74. Ugrinova I., Pasheva E.A., Armengaud J., and Pashev I.G. In vivo acetylation of HMG1 protein enhances its binding affinity to distorted DNA structures. Biochemistry 40 (2001) 14655-14660
75. Assenberg R., Webb M., Connolly E., Stott K., Watson M., Hobbs J., and Thomas J.O. A critical role in structure-specific DNA binding for the acetylatable lysine residues in HMGB1. Biochem. J. 411 (2008) 553-561
76. Ugrinova I., Pashev I.G., and Pasheva E.A. Post-synthetic acetylation of HMGB1 protein modulates its interactions with supercoiled DNA. Mol. Biol. Rep. 36 (2009) 1399-1404
77. Topalova D., Ugrinova I., Pashev I.G., and Pasheva E.A. HMGB1 protein inhibits DNA replication in vitro: a role of the acetylation and the acidic tail. Int. J. Biochem. Cell Biol. 40 (2008) 1536-1542
78. Bonaldi T., Talamo F., Scaffidi P., Ferrera D., Porto A., Bachi A., Rubartelli A., Agresti A., and Bianchi M.E. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22 (2003) 5551-5560
79. Ramachandran C., Yau P., Bradbury E.M., Shyamala G., Yasuda H., and Walsh D.A. Phosphorylation of high-mobility-group proteins by the calcium-phospholipid-dependent protein kinase and the cyclic AMP-dependent protein kinase. J. Biol. Chem. 259 (1984) 13495-13503
80. Youn J.H., and Shin J.S. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J. Immunol. 177 (2006) 7889-7897
81. Mantell L.L., Parrish W.R., and Ulloa L. HMGB-1 as a therapeutic target for infectious and inflammatory disorders. Shock 25 (2006) 4-11
82. Wang H., Zhu S., Zhou R., Li W., and Sama A.E. Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev. Mol. Med. 10 (2008) e32
83. Oh Y.J., Youn J.H., Ji Y., Lee S.E., Lim K.J., Choi J.E., and Shin J.S. HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J. Immunol. 182 (2009) 5800-5809
84. Zhang X., Wheeler D., Tang Y., Guo L., Shapiro R.A., Ribar T.J., Means A.R., Billiar T.R., Angus D.C., and Rosengart M.R. Calcium/calmodulin-dependent protein kinase (CaMK) IV mediates nucleocytoplasmic shuttling and release of HMGB1 during lipopolysaccharide stimulation of macrophages. J. Immunol. 181 (2008) 5015-5023
85. Ito I., Fukazawa J., and Yoshida M. Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J. Biol. Chem. 282 (2007) 16336-16344
86. Bustin M., Lehn D.A., and Landsman D. Structural features of the HMG chromosomal proteins and their genes. Biochim. Biophys. Acta 1049 (1990) 231-243
87. Sandeen G., Wood W.I., and Felsenfeld G. The interaction of high mobility proteins HMG14 and 17 with nucleosomes. Nucleic Acids Res. 8 (1980) 3757-3778
88. Hock R., Scheer U., and Bustin M. Chromosomal proteins HMG-14 and HMG-17 are released from mitotic chromosomes and imported into the nucleus by active transport. J. Cell Biol. 143 (1998) 1427-1436
89. Trieschmann L., Postnikov Y.V., Rickers A., and Bustin M. Modular structure of chromosomal proteins HMG-14 and HMG-17: definition of a transcriptional enhancement domain distinct from the nucleosomal binding domain. Mol. Cell. Biol. 15 (1995) 6663-6669
90. Ding H.F., Bustin M., and Hansen U. Alleviation of histone H1-mediated transcriptional repression and chromatin compaction by the acidic activation region in chromosomal protein HMG-14. Mol. Cell. Biol. 17 (1997) 5843-5855
91. Crippa M.P., Alfonso P.J., and Bustin M. Nucleosome core binding region of chromosomal protein HMG-17 acts as an independent functional domain. J. Mol. Biol. 228 (1992) 442-449
92. Bustin M. Chromatin unfolding and activation by HMGN(*) chromosomal proteins. Trends Biochem. Sci. 26 (2001) 431-437
93. Hock R., Wilde F., Scheer U., and Bustin M. Dynamic relocation of chromosomal protein HMG-17 in the nucleus is dependent on transcriptional activity. EMBO J. 17 (1998) 6992-7001
94. Phair R.D., and Misteli T. High mobility of proteins in the mammalian cell nucleus. Nature 404 (2000) 604-609
95. Rattner B.P., Yusufzai T., and Kadonaga J.T. HMGN proteins act in opposition to ATP-dependent chromatin remodeling factors to restrict nucleosome mobility. Mol. Cell 34 (2009) 620-626
96. Bhorjee J.S. Differential phosphorylation of nuclear nonhistone high mobility group proteins HMG 14 and HMG 17 during the cell cycle. Proc. Natl. Acad. Sci. U. S. A. 78 (1981) 6944-6948
97. Spaulding S.W., Fucile N.W., Bofinger D.P., and Sheflin L.G. Cyclic adenosine 3′,5′-monophosphate-dependent phosphorylation of HMG 14 inhibits its interactions with nucleosomes. Mol. Endocrinol. 5 (1991) 42-50
98. Palvimo J., and Maenpaa P.H. Binding of high-mobility-group proteins HMG 14 and HMG 17 to DNA and histone H1 as influenced by phosphorylation. Biochim. Biophys. Acta 952 (1988) 172-180
99. Palvimo J., Linnala-Kankkunen A., and Maenpaa P.H. Phosphorylation alters the affinity of high mobility group protein HMG 14 for single-stranded DNA. Biochem. Biophys. Res. Commun. 133 (1985) 343-346
100. Lund T., and Berg K. Metaphase-specific phosphorylations weaken the association between chromosomal proteins HMG 14 and 17, and DNA. FEBS Lett. 289 (1991) 113-116
101. Louie D.F., Gloor K.K., Galasinski S.C., Resing K.A., and Ahn N.G. Phosphorylation and subcellular redistribution of high mobility group proteins 14 and 17, analyzed by mass spectrometry. Protein Sci. 9 (2000) 170-179
102. Saffer J.D., and Glazer R.I. The phosphorylation of high mobility group proteins 14 and 17 and their distribution in chromatin. J. Biol. Chem. 257 (1982) 4655-4660
103. Palvimo J., Mahonen A., and Maenpaa P.H. Phosphorylation of high-mobility-group chromatin proteins by protein kinase C from rat brain. Biochim. Biophys. Acta 931 (1987) 376-383
104. Walton G.M., Spiess J., and Gill G.N. Phosphorylation of high mobility group 14 protein by cyclic nucleotide-dependent protein kinases. J. Biol. Chem. 257 (1982) 4661-4668
105. Palvimo J., Linnala-Kankkunen A., and Maenpaa P.H. Differential phosphorylation of high mobility group protein hmg 14 from calf thymus and avian erythrocytes by a cyclic gmp-dependent protein kinase. Biochem. Biophys. Res. Commun. 110 (1983) 378-382
106. Walton G.M., Spiess J., and Gill G.N. Phosphorylation of high mobility group protein 14 by casein kinase II. J. Biol. Chem. 260 (1985) 4745-4750
107. Soloaga A., Thomson S., Wiggin G.R., Rampersaud N., Dyson M.H., Hazzalin C.A., Mahadevan L.C., and Arthur J.S. MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J. 22 (2003) 2788-2797
108. Thomson S., Clayton A.L., Hazzalin C.A., Rose S., Barratt M.J., and Mahadevan L.C. The nucleosomal response associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase. EMBO J. 18 (1999) 4779-4793
109. Catez F., Brown D.T., Misteli T., and Bustin M. Competition between histone H1 and HMGN proteins for chromatin binding sites. EMBO Rep. 3 (2002) 760-766
110. Catez F., Yang H., Tracey K.J., Reeves R., Misteli T., and Bustin M. Network of dynamic interactions between histone H1 and high-mobility-group proteins in chromatin. Mol. Cell. Biol. 24 (2004) 4321-4328
111. Lim J.H., Catez F., Birger Y., West K.L., Prymakowska-Bosak M., Postnikov Y.V., and Bustin M. Chromosomal protein HMGN1 modulates histone H3 phosphorylation. Mol. Cell 15 (2004) 573-584
112. Prymakowska-Bosak M., Misteli T., Herrera J.E., Shirakawa H., Birger Y., Garfield S., and Bustin M. Mitotic phosphorylation prevents the binding of HMGN proteins to chromatin. Mol. Cell. Biol. 21 (2001) 5169-5178
113. Prymakowska-Bosak M., Hock R., Catez F., Lim J.H., Birger Y., Shirakawa H., Lee K., and Bustin M. Mitotic phosphorylation of chromosomal protein HMGN1 inhibits nuclear import and promotes interaction with 14.3.3 proteins. Mol. Cell. Biol. 22 (2002) 6809-6819
114. Zou Y., Jiang X., and Wang Y. Identification of novel in vivo phosphorylation sites in high mobility group N1 protein from the MCF-7 human breast cancer cells. Biochemistry 43 (2004) 6322-6329
115. Sterner R., Vidali G., and Allfrey V.G. Studies of acetylation and deacetylation in high mobility group proteins. Identification of the sites of acetylation in high mobility group proteins 14 and 17. J. Biol. Chem. 256 (1981) 8892-8895
116. Bergel M., Herrera J.E., Thatcher B.J., Prymakowska-Bosak M., Vassilev A., Nakatani Y., Martin B., and Bustin M. Acetylation of novel sites in the nucleosomal binding domain of chromosomal protein HMG-14 by p300 alters its interaction with nucleosomes. J. Biol. Chem. 275 (2000) 11514-11520
117. Herrera J.E., Sakaguchi K., Bergel M., Trieschmann L., Nakatani Y., and Bustin M. Specific acetylation of chromosomal protein HMG-17 by PCAF alters its interaction with nucleosomes. Mol. Cell. Biol. 19 (1999) 3466-3473
118. Ueda T., Postnikov Y.V., and Bustin M. Distinct domains in high mobility group N variants modulate specific chromatin modifications. J. Biol. Chem. 281 (2006) 10182-10187
119. Postnikov Y.V., Belova G.I., Lim J.H., and Bustin M. Chromosomal protein HMGN1 modulates the phosphorylation of serine 1 in histone H2A. Biochemistry 45 (2006) 15092-15099
120. Kim Y.C., Gerlitz G., Furusawa T., Catez F., Nussenzweig A., Oh K.S., Kraemer K.H., Shiloh Y., and Bustin M. Activation of ATM depends on chromatin interactions occurring before induction of DNA damage. Nat. Cell Biol. 11 (2009) 92-96
121. Adair J.E., Kwon Y., Dement G.A., Smerdon M.J., and Reeves R. Inhibition of nucleotide excision repair by high mobility group protein HMGA1. J. Biol. Chem. 280 (2005) 32184-32192
122. Maloney S.C., Adair J.E., Smerdon M.J., and Reeves R. Gene-specific nucleotide excision repair is impaired in human cells expressing elevated levels of high mobility group A1 nonhistone proteins. DNA Repair 6 (2007) 1371-1379
123. Adair J.E., Maloney S.C., Dement G.A., Wertzler K.J., Smerdon M.J., and Reeves R. High-mobility group A1 proteins inhibit expression of nucleotide excision repair factor xeroderma pigmentosum group A. Cancer Res. 67 (2007) 6044-6052
124. Li A.Y., Boo L.M., Wang S.Y., Lin H.H., Wang C.C., Yen Y., Chen B.P., Chen D.J., and Ann D.K. Suppression of nonhomologous end joining repair by overexpression of HMGA2. Cancer Res. 69 (2009) 5699-5706
125. Yuan F., Gu L., Guo S., Wang C., and Li G.M. Evidence for involvement of HMGB1 protein in human DNA mismatch repair. J. Biol. Chem. 279 (2004) 20935-20940
126. Krynetski E.Y., Krynetskaia N.F., Bianchi M.E., and Evans W.E. A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Res. 63 (2003) 100-106
127. Huang J.C., Zamble D.B., Reardon J.T., Lippard S.J., and Sancar A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 10394-10398
128. Lange S.S., Mitchell D.L., and Vasquez K.M. High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 10320-10325
129. Birger Y., West K.L., Postnikov Y.V., Lim J.H., Furusawa T., Wagner J.P., Laufer C.S., Kraemer K.H., and Bustin M. Chromosomal protein HMGN1 enhances the rate of DNA repair in chromatin. EMBO J. 22 (2003) 1665-1675